Precedex (Dexmedetomidine In 0.9 % NaCl) Patent Expiration, LOE Window & CMS Spending

Precedex (Dexmedetomidine In 0.9 % NaCl) by Pfizer: FDA Orange Book LOE 2032-07-04, 0 AB generics, $3.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN021038 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-07-04
Orange Book Patents (*PED Extensions)13 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$3.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.